Support for Narrow-Spectrum Antibiotics in Pediatric Pneumonia
Similar outcomes as broad-spectrum antibiotics for pediatric community-acquired pneumonia
TUESDAY, Dec. 10, 2013 (HealthDay News) -- Narrow-spectrum antibiotics, which are recommended as first-line therapy for children hospitalized with community-acquired pneumonia (CAP), show similar outcomes compared with broad-spectrum antibiotics, according to research published online Dec. 9 in Pediatrics.
Mary Ann Queen, M.D., of the University of Missouri in Kansas City, and colleagues retrospectively analyzed data from a cohort of children, aged 2 months to 18 years, to compare the effectiveness of empiric treatment with narrow-spectrum versus broad-spectrum antibiotic therapy for uncomplicated CAP.
The researchers found that, among 492 children hospitalized with CAP, 52 percent received empirical treatment with a narrow-spectrum agent and 48 percent received a broad-spectrum agent. In adjusted analysis, patients receiving the narrow-spectrum agent had a 10-hour shorter length of stay than those receiving the broad-spectrum agent (P = 0.04). No significant differences were observed between the groups for other outcomes, including duration of supplemental oxygen, duration of fever, or seven-day readmission. No difference was observed between the groups in average daily standardized cost (P = 0.62) or average daily standardized pharmacy cost (P = 0.26).
"Compared with broad-spectrum agents, narrow-spectrum antibiotic coverage is associated with similar outcomes," the authors write. "Our findings support national consensus recommendations for the use of narrow-spectrum antibiotics in children hospitalized with community-acquired pneumonia."